Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne

NCT02502669 is registered in ClinicalTrials.gov with Elorac, Inc. as lead sponsor.

NCT NCT02502669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02502669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Lead sponsor
Elorac, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
June 6, 2017
Enrollment
106 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

nodulocystic acne